We’re all here for one reason: the research for a cure! We’re in a pivotal moment for T1D research, and funding is more important than ever. As we continue to fight for a world without T1D, let’s take a moment to recognize some of the crucial work being done by JDRF- funded research!
ViaCyte, a regenerative medicine company long-supported by JDRF, today announced $27 million in financing to continue the development of beta cell therapies for diabetes. This funding ensures that Viacyte’s innovative approaches to replacing the insulin-producing beta cells in people with type 1 diabetes (T1D) will keep progressing.
The American Diabetes Association’s (ADA) 80th Scientific Sessions is almost here! From June 12-16, scientists and healthcare professionals will gather, virtually, at one of the largest conferences of diabetes researchers in the world. JDRF researchers and JDRF-funded scientists will also be there virtually to hear first-hand and present new study results that will improve outcomes for people with T1D.
JDRF funds type 1 diabetes (T1D) clinical trials that are critical to bringing new devices and treatments to people with this disease. Currently, there are more than 70 JDRF-funded clinical trials, to both prevent and treat this disease and its complications. We hope that, ultimately, these trials will lead to a cure for T1D.